ECSP088395A - Método de producción proteica utilizando compuestos anti-senescencia - Google Patents

Método de producción proteica utilizando compuestos anti-senescencia

Info

Publication number
ECSP088395A
ECSP088395A EC2008008395A ECSP088395A ECSP088395A EC SP088395 A ECSP088395 A EC SP088395A EC 2008008395 A EC2008008395 A EC 2008008395A EC SP088395 A ECSP088395 A EC SP088395A EC SP088395 A ECSP088395 A EC SP088395A
Authority
EC
Ecuador
Prior art keywords
cell culture
production method
protein production
senescence
senescence compound
Prior art date
Application number
EC2008008395A
Other languages
English (en)
Inventor
Denis Drapeau
Yen-Tung Luan
Wenge Wang
Paul Thoday
Judy Chou
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37873105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088395(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088395A publication Critical patent/ECSP088395A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan métodos para producir una proteína en cultivo celular que comprende un compuesto anti-senescencia, tal como el antioxidante carnosina. De acuerdo con las enseñanzas de la presente invención, las células cultivadas en un medio de cultivo celular que comprende un compuesto anti-senescencia exhiben mayor viabilidad y productividad. Adicionalmente, los cultivos celulares cultivados en presencia de un compuesto anti-senescencia exhiben niveles reducidos de agregados de elevado peso molecular en el medio de cultivo celular.
EC2008008395A 2005-10-24 2008-04-23 Método de producción proteica utilizando compuestos anti-senescencia ECSP088395A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72957305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
ECSP088395A true ECSP088395A (es) 2008-05-30

Family

ID=37873105

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008395A ECSP088395A (es) 2005-10-24 2008-04-23 Método de producción proteica utilizando compuestos anti-senescencia

Country Status (23)

Country Link
US (1) US20070110743A1 (es)
EP (1) EP1941026B1 (es)
JP (2) JP2009512459A (es)
KR (1) KR101402634B1 (es)
CN (1) CN101297027B (es)
AR (1) AR058140A1 (es)
AU (1) AU2006306433B2 (es)
BR (1) BRPI0617744A2 (es)
CA (1) CA2627003C (es)
CR (1) CR9897A (es)
DK (1) DK1941026T3 (es)
EC (1) ECSP088395A (es)
ES (1) ES2485374T3 (es)
IL (1) IL190550A (es)
NI (1) NI200800111A (es)
NO (1) NO20081622L (es)
PE (1) PE20070796A1 (es)
PL (1) PL1941026T3 (es)
PT (1) PT1941026E (es)
RU (1) RU2491347C2 (es)
SI (1) SI1941026T1 (es)
TW (1) TW200736397A (es)
WO (1) WO2007050498A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101495549B1 (ko) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
MX353340B (es) 2006-09-13 2018-01-09 Abbvie Inc Mejoras de cultivos celulares.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
US8859235B2 (en) 2009-08-14 2014-10-14 Basf Se Methods in cell cultures, and related inventions, employing certain additives
EP2601287B1 (en) 2010-08-05 2015-01-07 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
EP2611904A2 (en) * 2010-08-31 2013-07-10 Friesland Brands B.V. Culture medium for eukaryotic cells
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
TW201247874A (en) * 2011-05-25 2012-12-01 United Biomedical Inc Method for producing the activity of bone activating protein
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014140890A2 (en) * 2013-03-13 2014-09-18 Neocutis Sa Peptides for skin rejuvenation and methods of using the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014145098A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
JP6526025B2 (ja) 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN104398398A (zh) * 2014-10-27 2015-03-11 陈少威 一种细胞量子动力素(平衡剂)及其使用方法
MA40864A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017083224A1 (en) * 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
AU2017206012A1 (en) * 2016-01-06 2018-07-26 Outlook Therapeutics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
SG11202001127TA (en) * 2017-10-16 2020-03-30 Regeneron Pharma In situ raman spectroscopy systems and methods for controlling process variables in cell cultures
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN121773198A (zh) * 2023-09-05 2026-03-31 味之素株式会社 培养基组合物
AR134845A1 (es) * 2023-12-25 2026-04-29 Takeda Pharmaceuticals Co Método de cultivo celular

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992009298A1 (en) * 1990-11-23 1992-06-11 Peptide Technology Ltd. The delay, prevention and/or reversal of cell senescence
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
RU2245365C2 (ru) * 1994-01-03 2005-01-27 Генентек Инк. Тромбопоэтин
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
RU2134120C1 (ru) * 1995-06-26 1999-08-10 Безруков Михаил Васильевич Средство для стабилизации пептидной связи в белковом препарате
ATE219517T1 (de) * 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
ATE549918T1 (de) * 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
JP4261195B2 (ja) * 2001-04-24 2009-04-30 イノジェネティックス・ナムローゼ・フェンノートシャップ 酵母のコア−グリコシル化されたｈｃｖエンベロープタンパク質の発現
AU2003300276B2 (en) * 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
RU2409591C2 (ru) * 2003-10-27 2011-01-20 Вайет Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах
WO2005064013A1 (en) * 2003-12-23 2005-07-14 Bart Janssen The use of carnosine metabolism-associated genes to determine genetic predisposition/susceptibility to diabetic nephropathy
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7426440B2 (en) * 2004-09-24 2008-09-16 Nutritional Bioscience Ltd. Repair and protection factor scoring method for bioactive agents

Also Published As

Publication number Publication date
KR20080063365A (ko) 2008-07-03
CA2627003A1 (en) 2007-05-03
IL190550A0 (en) 2008-11-03
SI1941026T1 (sl) 2014-07-31
NO20081622L (no) 2008-06-18
RU2491347C2 (ru) 2013-08-27
WO2007050498A3 (en) 2007-07-12
EP1941026A2 (en) 2008-07-09
NI200800111A (es) 2009-03-03
HK1120552A1 (en) 2009-04-03
JP2013165728A (ja) 2013-08-29
TW200736397A (en) 2007-10-01
JP5907928B2 (ja) 2016-04-26
BRPI0617744A2 (pt) 2011-08-02
JP2009512459A (ja) 2009-03-26
CN101297027B (zh) 2013-04-03
EP1941026B1 (en) 2014-06-04
CR9897A (es) 2008-07-29
AU2006306433A1 (en) 2007-05-03
DK1941026T3 (da) 2014-07-21
KR101402634B1 (ko) 2014-06-03
PT1941026E (pt) 2014-07-31
US20070110743A1 (en) 2007-05-17
CN101297027A (zh) 2008-10-29
RU2008113220A (ru) 2009-12-10
PL1941026T3 (pl) 2014-12-31
AR058140A1 (es) 2008-01-23
PE20070796A1 (es) 2007-08-15
IL190550A (en) 2017-01-31
WO2007050498A2 (en) 2007-05-03
ES2485374T3 (es) 2014-08-13
AU2006306433B2 (en) 2013-04-18
CA2627003C (en) 2018-08-28

Similar Documents

Publication Publication Date Title
NI200800111A (es) Método de producción proteica utilizando compuestos anti-senescencia
PA8778001A1 (es) Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescencia
AR090822A1 (es) Composiciones de cultivo de celulas y metodos para la produccion de polipeptidos
WO2008060541A3 (en) In vitro expansion of postpartum-derived cells using microcarriers
CU20120006A7 (es) Producción de títulos elevados de poliovirus para la producción de vacunas
CO6531436A2 (es) Métodos de producción de glucoproteínas en cultivos de celulas de mamiferos usando glucocorticoides
MX2013014937A (es) Cultivo de celulas de mamifero.
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
EP2588594A4 (en) PROCESS FOR CULTIVATING UNDIFFERENCED CELLS USING DELAYED RELATED COMPOSITION COMPOSITIONS
ATE540975T1 (de) Verbesserte faktor-viii-polypeptid-titer in zellkulturen
MY156588A (en) Systems using cell culture for production of isoprene
NZ592159A (en) Means and methods for influencing the stability of antibody producing cells
WO2008154014A3 (en) A method for culturing mammalian cells to improve recombinant protein production
NO20072719L (no) Serumfritt cellekulturmedium for pattedyrceller
MX2015010841A (es) Modificacion genetica de ratas.
EA201170024A1 (ru) Способы получения высокой плотности жизнеспособных клеток в культуре клеток млекопитающих
BR112015023036A2 (pt) método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina
MX360779B (es) Composiciones de cultivo celular con antioxidantes y métodos para la producción de polipéptidos.
CR11827A (es) Activadores de glucoquinasa
MX356756B (es) Células madre pluripotentes en microportadores.
AR109907A2 (es) Métodos para la producción de proteínas morfogenéticas óseas
EP4446338A3 (en) Cells and method of cell culture
CR20160307A (es) Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas
UY32732A (es) Medios para cultivo de células de mamíferos que comprenden sobrenadante del fraccionamiento de cohn y uso de los mismos
MX2018006373A (es) Produccion de virus en cultivos celulares.